Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Vence

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Diabetes|October 27, 2004
Fas deficiency prevents type 1 diabetes by inducing hyporesponsiveness in islet beta-cell-reactive T-cellsLuis Vence, Christophe Benoist, Diane Mathis
Expert Review of Vaccines|June 4, 2010
Development and application of 'phosphoflow' as a tool for immunomonitoringSheng Wu, Lei Jin, Luis Vence, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitroYufeng Li, Shujuan Liu, Jessica Hernandez, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2021
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinomaLi Cheng, Todd Creasy, Fernanda Pilataxi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanomaLuis Vence, A Karolina Palucka, Joseph W Fay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2019
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers-ResponseAnu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human CancersAnu Sharma, Sumit K Subudhi, Jorge Blando, et al.
International Journal of Oncology|January 1, 2010
Cytotoxic effects of ultra-diluted remedies on breast cancer cellsMoshe Frenkel, Bal Mukund Mishra, Subrata Sen, et al.
Cancer Immunology Research|July 11, 2019
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular CarcinomaAhmed Omar Kaseb, Luis Vence, Jorge Blando, et al.
Journal of Hematology & Oncology|September 7, 2016
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportMarc Uemura, Van A Trinh, Cara Haymaker, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Diabetes|October 27, 2004
Fas deficiency prevents type 1 diabetes by inducing hyporesponsiveness in islet beta-cell-reactive T-cellsLuis Vence, Christophe Benoist, Diane Mathis
Expert Review of Vaccines|June 4, 2010
Development and application of 'phosphoflow' as a tool for immunomonitoringSheng Wu, Lei Jin, Luis Vence, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitroYufeng Li, Shujuan Liu, Jessica Hernandez, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2021
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinomaLi Cheng, Todd Creasy, Fernanda Pilataxi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanomaLuis Vence, A Karolina Palucka, Joseph W Fay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2019
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers-ResponseAnu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human CancersAnu Sharma, Sumit K Subudhi, Jorge Blando, et al.
International Journal of Oncology|January 1, 2010
Cytotoxic effects of ultra-diluted remedies on breast cancer cellsMoshe Frenkel, Bal Mukund Mishra, Subrata Sen, et al.
Cancer Immunology Research|July 11, 2019
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular CarcinomaAhmed Omar Kaseb, Luis Vence, Jorge Blando, et al.
Journal of Hematology & Oncology|September 7, 2016
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportMarc Uemura, Van A Trinh, Cara Haymaker, et al.
Pageof 3